Breaking News Instant updates and real-time market news.

RHHBY

Roche

$0.00

(0.00%)

, ACIU

AC Immune

$16.45

0.47 (2.94%)

04:55
07/26/18
07/26
04:55
07/26/18
04:55

Alzheimer's Association to hold a conference

Alzheimer's Association International Conference 2018: AAIC 2018 will be held in Chicago on July 22-26.

RHHBY

Roche

$0.00

(0.00%)

ACIU

AC Immune

$16.45

0.47 (2.94%)

LLY

Eli Lilly

$96.44

3.12 (3.34%)

AXSM

Axsome Therapeutics

$2.88

-0.15 (-4.96%)

SPPI

Spectrum

$22.10

-0.44 (-1.95%)

PRAH

PRA Health

$106.90

2 (1.91%)

PKI

PerkinElmer

$79.22

0.5 (0.64%)

NTRP

Neurotrope

$9.93

0.04 (0.40%)

ESALY

Eisai

$0.00

(0.00%)

DNA

Bought by RHHBY

$0.00

(0.00%)

DGX

Quest Diagnostics

$107.65

2.24 (2.13%)

ACAD

Acadia

$16.05

0.05 (0.31%)

ABBV

AbbVie

$93.13

1.6 (1.75%)

  • 27

    Jul

  • 01

    Aug

  • 02

    Aug

  • 08

    Aug

  • 10

    Sep

RHHBY Roche
$0.00

(0.00%)

07/11/18
WELS
07/11/18
NO CHANGE
WELS
Drug stocks may not react favorably to Pfizer price rollback, Trump tweets, says Wells Fargo
Wells Fargo analyst David Maris notes that there was widespread media coverage of drug price increases taken recently by several large cap drug companies, with President Trump criticizing Pfizer (PFE) for taking these price increases. On Tuesday, Pfizer confirmed it was rolling back its July drug price increases following a conversation with President Trump, he adds. Maris believes that drug stocks will not react favorably to this news, given the chilling effect this will likely have on others looking to take price increases. Nonetheless, the analyst points out that the price increases taken in July are only a small number of increases taken over the past year or several years, so the impact of the rollback to the healthcare system is insignificant in the big picture. Other publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
07/11/18
PIPR
07/11/18
NO CHANGE
Target $365
PIPR
Overweight
Biogen price target raised to $365 from $353 at Piper Jaffray
Piper Jaffray analyst Christopher Raymond raised his price target for Biogen (BIIB) to $365 saying a survey of 101 neurologists gives him increased confidence in the staying power of the company's multiple sclerosis franchise. Tecfidera market share "edged up slightly" during the quarter, and the survey shows signs of Roche's (RHHBY) Ocrevus "hitting a bit of a wall," Raymond tells investors in a research note. Further, the analyst continues to hear feedback that Celgene's (CELG) ozanimod "will be minimally differentiated." Despite increased signs of payer activism in the space, Biogen's MS franchise is well positioned for the near-to-intermediate term, Raymond contends. He raised his estimates for Tecfidera and keeps an Overweight rating on Biogen.
06/28/18
WELS
06/28/18
NO CHANGE
WELS
Wells says Amazon deal, Walgreens results have negative read for drug pricing
After Amazon (AMZN) agreed to acquire online pharmacy PillPack, reportedly for $1B, Wells Fargo analyst David Maris noted that he has long stated that Amazon would enter the pharmacy business and warned about the risk to drug pricing in such a scenario. Maris also noted that Walgreens (WBA) reported its U.S. retail pharmacy comparable store sales fell 1.2% in Q3, adding that retailers tend to push drugmakers on price when they feel pressure and the read-through from its report may be negative for drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/11/18
ADAM
07/11/18
NO CHANGE
Target $140
ADAM
Buy
Celgene's Buy rating backed at Canaccord following Phase 3 Impassion130 results
Canaccord analyst John Newman maintained a Buy rating and $140 price target on Celgene (CELG) after the company said that the Phase 3 Impassion130 study showed progression-free survival, or PFS, improvement for 1L metastatic or unresectable triple negative breast cancer with Abraxane plus Tecentriq (RHHBY) , which opens the door to Tencentriq in this indication. In a research note to investors, Newman says he expects continued upside from pipeline advances and diversification based on in-licensing, M&A and organic R&D and that, as there are currently no alternatives to chemotherapy, the combination of Abraxane plus Tecentriq should see widespread use if approved. He views the advances in TNBC "very positively" given the high unmet need for viable therapy.
ACIU AC Immune
$16.45

0.47 (2.94%)

03/23/18
FBCO
03/23/18
DOWNGRADE
FBCO
Neutral
AC Immune downgraded to Neutral from Outperform at Credit Suisse
04/05/18
HCWC
04/05/18
INITIATION
Target $18
HCWC
Buy
AC Immune initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein started AC Immune with a Buy rating and $18 price target. The analyst believes the company's "risk mitigated" approach to Alzheimer's drug development is underappreciated.
LLY Eli Lilly
$96.44

3.12 (3.34%)

07/25/18
BMOC
07/25/18
NO CHANGE
Target $90
BMOC
Market Perform
Eli Lilly price target raised to $90 from $80 at BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Eli Lilly to $90, saying the company is doing an "excellent" job in managing its mature franchises and should finish 2018 at the top end of its guidance. The analyst also believes that the company can achieve its 2015-20 annual revenue growth target of 5% or more. Arfaeil keeps his Market Perform rating however, noting that its valuation reflects the opportunities around Tanezumab, migraine and Alzheimer's franchises while also pointing to the "underappreciated" risks around its insulins franchise.
07/25/18
CANT
07/25/18
NO CHANGE
Target $110
CANT
Overweight
Eli Lilly price target raised to $110 from $100 at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen yesterday raised her price target for Eli Lilly to $110 citing the company's beat and raise quarter. The growth prospects for Lilly's key drugs - Trulicity, Jardiance, Taltz and Verzenio - as well as its pipeline assets, especially in pain, are underappreciated, Chen told investors in a post-earnings research note. She reiterates an Overweight rating on the shares.
07/25/18
07/25/18
DOWNGRADE
Target $99

Hold
Eli Lilly downgraded to Hold on valuation at Berenberg
As previously reported, Berenberg analyst Laura Sutcliffe downgraded Eli Lilly to Hold from Buy, stating that the company reported "very good" Q2 results and its sales growth is built on the "solid proposition" of Trulicity, but the company is in the process of re-stocking its late-stage pipeline both internally and via deals. While she thinks Lilly's premium to peers is deserved, Sutcliffe also sees the stock at a "reasonably full valuation" at current levels, she tells investors. She trimmed her price target on Lilly shares to $99 from $100.
07/25/18
07/25/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Spotify (SPOT) downgraded to Hold from Buy at Pivotal Research with analyst Jeffrey Wlodarczak citing valuation. 2. Eli Lilly (LLY) downgraded to Hold from Buy at Berenberg with analyst Laura Sutcliffe saying the company reported "very good" Q2 results and its sales growth is built on the "solid proposition" of Trulicity, but the company is in the process of re-stocking its late-stage pipeline both internally and via deals. 3. Walmart (WMT) downgraded to Hold from Accumulate at Gordon Haskett with analyst Chuck Grom saying he thinks there are few near-term catalysts on the horizon and the margin outlook is not as transparent following a period of improvement and stabilization, and expects shares to be range bound for the balance of the year. 4. Hormel Foods (HRL) downgraded to Underperform from Neutral at Mizuho with analyst Jeremy Scott saying "volatile and retreating" pork margins bring rising risks to Hormel's earnings. 5. BJ's Wholesale (BJ) downgraded to Accumulate from Buy at Gordon Haskett with analyst Chuck Grom citing share strength following the IPO. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
AXSM Axsome Therapeutics
$2.88

-0.15 (-4.96%)

06/07/18
06/07/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Xencor (XNCR) initiated with a Buy at BTIG. 2. Donnelley Financial Solutions (DFIN) initiated with a Buy at DA Davidson. 3. Axsome Therapeutics (AXSM) initiated with a Buy at H.C. Wainwright. 4. ShotSpotter (SSTI) initiated with an Outperform at JMP Securities. 5. WellCare (WCG) initiated with a Buy at Argus. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/26/17
LTCO
07/26/17
NO CHANGE
Target $31
LTCO
Buy
Axsome Therapeutics price target raised to $31 from $28 at Ladenburg
Ladenburg Thalmann analyst Matthew Kaplan raised his price target for Axsome Therapeutics to $31 after the company provided details on AXS-06, its third clinical program. The positive Phase 1 data demonstrated AXS-06 is a differentiated product based on its reduction of time to maximal concentration to 30 minutes versus 4.5 hours for Mobic, the analyst tells investors in a research note. He reiterates a Buy rating on Axsome.
06/07/18
HCWC
06/07/18
INITIATION
Target $10
HCWC
Buy
Axsome Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju started Axsome Therapeutics with a Buy rating and $10 price target. n concentrating on compounds that are well-established from a safety and activity profile perspective, Axsome eliminates some of the risks associated with conducting central nervous system-centric drug development, the analyst contends. He believes the company has a broad clinial-stage pipeline with multiple shots on goal.
SPPI Spectrum
$22.10

-0.44 (-1.95%)

03/13/18
HCWC
03/13/18
NO CHANGE
Target $33
HCWC
Buy
Spectrum recent weakness a buying opportunity, says H.C. Wainwright
H.C. Wainwright analyst Edward White views the recent pullback in shares of Spectrum Pharmaceuticals as a buying opportunity. The next big clinical update for poziotinib is expected in the second half of 2018, most likely at the World Conference on Lung Cancer, White tells investors in a research note. He believes the recent stock price weakness is due to some investors believing that something is wrong with the study since data will not be at ASCO. The analyst, however, reiterates that he never expected to see data at ASCO. He continues to believe the MD Anderson study is proceeding as expected and keeps a Buy rating on Spectrum with a $33 price target.
02/05/18
HCWC
02/05/18
NO CHANGE
Target $33
HCWC
Buy
Spectrum price target raised to $33 from $29 at H.C. Wainwright
H.C. Wainwright analyst Edward White raised his price target for Spectrum Pharmaceuticals to $33 after the company's This Advance Phase 3 study met the primary efficacy endpoint of non-inferiority in duration of severe neutropenia between Rolontis and Neulasta. The analyst is encouraged by the positive top-line data and looks forward to the full data set. He continues to believe Rolontis has blockbuster potential and projects revenue of $650M in 2024. White keeps a Buy rating Spectrum.
04/10/18
RILY
04/10/18
NO CHANGE
Target $26
RILY
Buy
B. Riley FBR says Spectrum likely has one more meeting before poziotinib filing
After Spectrum reported that MD Anderson's Phase 2 study of poziotinib in patients with advanced nonsmall cell lung cancer with EGFR exon 20 mutations has fully enrolled its initial 30- patient cohort and updated on the initial 11 patients, B. Riley FBR analyst David Buck said he expects one more FDA meeting before a likely filing in 2018. He reiterates a Buy rating and $26 price target on Spectrum shares.
06/27/18
RILY
06/27/18
NO CHANGE
Target $26
RILY
Buy
Spectrum takeover report 'plausible,' says B. Riley FBR
Following a report from Bloomberg yesterday that Spectrum Pharmaceuticals is exploring options including a sale of the business amid takeover interest from other drugmakers, B. RIley FBR analyst David Buck told investors in a research note that while he has no confirmation of any takeover interest or sale process, he sees the report as "plausible." Buck, who reiterated a Buy rating, says that he continues to see his $26 per share target based on DCF and 2022E earnings power as "reasonable." Aide from any actual news on a potential transaction or sales process that gets confirmed, he expects further news flow on pipeline drug Rolontis, including a June 29 Spectrum-sponsored conference call and an expected presentation of additional poziotinib data at the World Lung Conference.
PRAH PRA Health
$106.90

2 (1.91%)

12/14/17
MUFG
12/14/17
INITIATION
Target $102
MUFG
Overweight
PRA Health initiated with an Overweight at MUFG
MUFG analyst Jason Twizell started PRA Health with an Overweight rating and $102 price target. The analyst finds the company's premium valuation justified given its high-teens percentage revenue growth outlook and "consistent" execution.
12/11/17
LEHM
12/11/17
INITIATION
Target $94
LEHM
Overweight
PRA Health initiated with an Overweight at Barclays
Barclays analyst Jack Meehan started PRA Health Sciences with an Overweight rating and $94 price target. The analyst views the stock's valuation as attractive in the context of the company's "market-leading growth rates." He believes the integration of data into clinical trials is going to become a "need to have."
10/30/17
KEYB
10/30/17
NO CHANGE
Target $93
KEYB
Overweight
PRA Health price target raised to $93 from $86 at KeyBanc
KeyBanc analyst Donald Hooker raised his price target for PRA Health to $93 from $86 to reflect the stronger than expected trends at Symphony Health and over 15% EBITDA growth in 2018 and 2019. The analyst reiterates an Overweight rating on the shares.
01/24/18
MZHO
01/24/18
DOWNGRADE
Target $86
MZHO
Neutral
PRA Health downgraded to Neutral from Buy at Mizuho
Mizuho analyst Ann Hynes downgraded PRA Health to Neutral citing valuation and trimmed its price target to $86 from $87.
PKI PerkinElmer
$79.22

0.5 (0.64%)

12/19/17
BOFA
12/19/17
UPGRADE
Target $78
BOFA
Neutral
PerkinElmer upgraded to Neutral from Underperform at BofA/Merrill
BofA/Merrill analyst Derik De Bruin upgraded PerkinElmer to Neutral and raised its price target to $78 from $70 ahead ot the pending $1.3B Eurolmmun acquisition. De Bruin said PerkinElmer has been pruning non-core and slower businesses and Eurolmmun is a key step in the portfolio transition with its solid and price competitive autoimmune testing business.
01/03/18
EVER
01/03/18
INITIATION
Target $77
EVER
In Line
PerkinElmer initiated with an In Line at Evercore ISI
Evercore ISI analyst Ross Muken initiated PerkinElmer with an In Line rating and $77 price target.
09/26/17
GSCO
09/26/17
INITIATION
Target $67
GSCO
Neutral
PerkinElmer assumed with a Neutral at Goldman Sachs
Goldman analyst Patrick Donnelly assumed coverage on PerkinElmer with a Neutral and $67 price target. The analyst expects below peer growth to continue and believes managements operating profit margin goal of 22% by 2020 is aggressive.
09/26/17
SBSH
09/26/17
NO CHANGE
Target $80
SBSH
Buy
PerkinElmer price target raised to $80 from $74 at Citi
Citi analyst Daniel Arias raised his price target for PerkinElmer shares to $80 after hosting meetings with management. The analyst left the meetings more optimistic that the company's ongoing portfolio evolution can drive a "material organic growth inflection." He maintains a Buy rating on PerkinElmer.
NTRP Neurotrope
$9.93

0.04 (0.40%)

03/08/18
ROTH
03/08/18
INITIATION
Target $15
ROTH
Buy
Neurotrope initiated with a Buy at Roth Capital
Roth Capital analyst Robert LeBoyer started Neurotrope with a Buy rating and $15 price target.
05/16/18
MAXM
05/16/18
INITIATION
Target $16
MAXM
Buy
Neurotrope initiated with a Buy at Maxim
Maxim started Neurotrope with a Buy rating and $16 price target.
ESALY Eisai
$0.00

(0.00%)

07/06/18
NOMU
07/06/18
UPGRADE
NOMU
Buy
Eisai upgraded to Buy from Neutral at Nomura Instinet
07/10/18
MZHO
07/10/18
NO CHANGE
MZHO
Buy
Biogen, Eisai not sharing details on BAN2401 presentation at AAIC, says Mizuho
After Biogen (BIIB) and partner Eisai's (ESALY) recent announcement that BAN2401 demonstrated statistically significant slowing in clinical decline and reduction of amyloid beta accumulation in a trial of Alzheimer's patients, Mizuho analyst Salim Syed said he has checked with both companies and neither is divulging any details about what sort of data on the trial will be shared at the upcoming AAIC meeting. He maintains a Buy rating and $423 price target on Biogen shares.
07/06/18
MSCO
07/06/18
NO CHANGE
Target $369
MSCO
Overweight
Biogen likely to be up 5%-10% on positive Alzheimer's data, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison said the fact that Eisai (ESALY) and Biogen's (BIIB) BAN2401 trial achieved positive topline results at an 18 month landmark analysis is a "clear positive" for the perception of aducanumab and he expects Biogen's shares to be up 5% to over 10% following the news. Harrison added that he would expect full data to be reported at the CTAD meeting in October as he thinks the AAIC meeting coming up in late July is too close. He keeps an Overweight rating and $369 price target on Biogen shares.
DNA Bought by RHHBY
$0.00

(0.00%)

10/13/17
KEYB
10/13/17
NO CHANGE
Target $106
KEYB
Overweight
Auto suppliers supported by stronger Euro and rising EU output, says KeyBanc
KeyBanc analyst Brett Hoselton raised his profit targets on several auto suppliers, maintaining a positive view on the group overall heading into Q3 earnings. Hoselton says the outlook for the quarter is intact, as lower than expected production of light vehicles was in part offset by stronger EU output. He also cites FX tailwinds, with the Euro have appreciated about 7% sequentially and further supporting revenue in Q3 and possibly FY18. Hoselton raised his profit targets on Delphi Automotive (DLPH) to $106 from $100, Magna International (MGA) to $59 from $55, Lear Corp (LEA) to $184 from $180, and BorgWarner (BWA) to $56 from $50, maintaining an Overweight rating on all these stocks. The analyst is especially bullish on Dana Inc (DNA) given the recent upward revisions to North America Class 8 production, but says his Sector Weight rating reflects the stock prices.
DGX Quest Diagnostics
$107.65

2.24 (2.13%)

07/10/18
07/10/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. CarMax (KMX) upgraded two notches to Overweight from Underweight at Morgan Stanley with analyst Armintas Sinkevicius saying longer term, he is constructive on dealers, citing a belief that tech disruption could accelerate consolidation and set up a transition toward "megafleet managers." 2. Cummins (CMI) upgraded to Buy from Hold at Stifel with analyst Michael Baudendistel saying shares of truck equipment companies have been under pressure primarily on concerns that the cycle is at a peak. 3. Wynn Resorts (WYNN) upgraded to Buy from Hold at Stifel with analyst Steven Wieczynski saying he believes the pullback in the stock recently has created a compelling opportunity. 4. KB Home (KBH) upgraded to Positive from Neutral at Susquehanna with analyst Jack Micenko citing a "clear and visible path" to further gross margin expansion and re-acceleration in community count and order growth well into 2019 for the upgrade, adding that underlying housing trends are strong in many of the markets in which the company currently operates despite "cautious" macro sentiment. 5. Quest Diagnostics (DGX) upgraded to Outperform from In Line at Evercore ISI with analyst Ross Muken saying the company will likely be the beneficiary of improved volumes, stable pricing, heightened M&A, and fund flows amid the heightened volatility within the Rx supply chain. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/25/18
ADAM
07/25/18
NO CHANGE
Target $118
ADAM
Buy
Quest Diagnostics decline fair, but big picture intact, says Canaccord
Canaccord analyst Mark Massaro said the decline in Quest Diagnostics shares following its Q2 miss and lowered top-line guidance was fair. Despite the miss, the analyst believes the story remains intact as he believes the company will take market share, is poised to win more business, and he expects the pace of M&A to increase. Massaro reiterated his Buy rating and lowered his price target to $118 from $122 on Quest Diagnostics shares.
07/25/18
BARD
07/25/18
NO CHANGE
Target $120
BARD
Outperform
Quest Diagnostics selloff understandable, but overdone, says Baird
Baird analyst Eric Coldwell said the selloff in Quest Diagnostics following its Q2 miss is understandable, but perhaps overdone. He believes the company's headwinds remain manageable and he doesn't think much has changed to the story with the exception of maybe a roughly 20 basis point revenue growth reduction. Coldwell reiterated his Outperform rating and $120 price target on Quest Diagnostics shares.
07/10/18
EVER
07/10/18
UPGRADE
Target $121
EVER
Outperform
Quest Diagnostics upgraded to Outperform at Evercore ISI on improved volume view
As reported earlier, Evercore ISI analyst Ross Muken upgraded Quest Diagnostics (DGX) to Outperform from In Line and raised his price target to $121 from $108. The analyst notes that the company will likely be the beneficiary of improved volumes, stable pricing, heightened M&A and fund flows amid the heightened volatility within the Rx supply chain. Muken believes that the company is "less exposed to political risk and big bad Amazon (AMZN)" competition, while its new management has also effectively reduced costs and deployed capital.
ACAD Acadia
$16.05

0.05 (0.31%)

11/06/17
LEER
11/06/17
NO CHANGE
Target $35
LEER
Market Perform
Data suggests Acadia pivotal DRP program is high risk, says Leerink
Following full data from Acadia's phase 2 study of pimavanserin in Alzheimer's Disease Psychosis patients at the Clinical Trials on Alzheimer's Disease, Leerink analyst Paul Matteis says his cautious view on the company's phase 3 dementia related psychosis program remains as the statistically significant benefit for pimavanserin seen at the primary endpoint of 6 weeks was in his view helped considerably by a temporary regression in placebo response, this dynamic was also the case in a featured, more severe subgroup, and dementia related psychosis is a chronic condition, and for any new medication a sustained clinical benefit will be important. He reiterates a Market Perform rating and $35 price target on the shares.
04/10/18
JPMS
04/10/18
NO CHANGE
Target $50
JPMS
Overweight
Acadia sees little impact from CNN article, says JPMorgan
JPMorgan analyst Cory Kasimov says Acadia Pharmaceuticals management stressed to him their confidence that yesterday's CNN article would have little impact on Nuplazid's commercial prospects. Kasimov says that while management believes the news changes nothing, he worries "that the already tenuous sentiment around the name could have a difficult time withstanding this latest development." It remains to be seen what extent, if any, the creased scrutiny on the safety profile of Nuplazid negatively impacts the product's commercial outlook, Kasimov tells investors in a research note. He believes Acadia'a Q1 earnings report now has even greater significance. The analyst keeps an Overweight rating on Acadia with a $50 price target.
04/10/18
COWN
04/10/18
NO CHANGE
Target $50
COWN
Outperform
Acadia pimavanserin concerns a reason for caution, says Cowen
Cowen analyst Ritu Baral noted yesterday's media report concerning deaths in the Acadia pimavanserin FAERS log. The analyst said based on conversations with key opinion leaders who have major experience with pimavanserin, she thinks there is unlikely a safety signal. However, she does say the concerns keep her cautious on the stock. Baral maintained her Outperform rating and $50 price target on Acadia shares, which dropped 23% to close at $16.50 yesterday.
04/26/18
JPMS
04/26/18
NO CHANGE
JPMS
Overweight
JPMorgan still sees low risk of Acadia drug being pulled from market
JPMorgan analyst Cory Kasimov continues to see a low, "but not zero," risk of Acadia Pharmaceuticals' Nuplazid being pulled from the market. Yesterday's CNN report is "mostly noise" and "nothing new," Kasimov told investors last night in a research note. The analyst, however, says he can appreciate the impact of the FDA Commissioner indicating he would "take another look" at the drug's safety profile. Kasimov predicates his views on the formal FDA review and the agency's initial statement that Nuplazid's safety profile is consistent with the label, as well as additional commentary he received yesterday from management. The analyst views yesterday's pullback in shares of Acadia as "fundamentally unjustified based on current information." He kept an Overweight rating on the stock. Shares of Acadia are up 5% to $15.95 in early trading.
ABBV AbbVie
$93.13

1.6 (1.75%)

07/24/18
SBSH
07/24/18
NO CHANGE
SBSH
Buy
Citi says Myovant may have $102 upside if relugolix priced at parity to elagolix
After AbbVie (ABBV) and Neurocrine Biosciences (NBIX) announced that the FDA approved elagolix and Neurocrine said the list price has been set at $28 per day, Citi analyst Robyn Karnauskas noted that she currently models Myovant Sciences' (MYOV) relugolix priced at $10 per day. Modeling relugolix pricing at parity to elagolix and assuming a gross-to-net of 100% would lead to a fair value estimate for Myovant of $146, or the equivalent of $102 of upside from her current price target of $44, Karnauskas stated. The analyst, who models a split market between relugolix and elagolix in endometriosis, keeps a Buy rating on Myovant shares.
06/22/18
FBCO
06/22/18
NO CHANGE
Target $89
FBCO
Underperform
AbbVie most exposed to biosimilar risk, says Credit Suisse
Credit Suisse analyst Vamil Divan reiterated an Underperform rating on AbbVie after the FDA further ramped up its focus on biosimilars. In a research note to investors, Divan said he was "intrigued" by the FDA's decision to withdraw its September 2017 Draft Guidance focused on evaluating analytical similarity with biosimilars, and believes the agency will release "more reasonable" guidance in the coming months that will expedite the approval and uptake of biosimilars. AbbVie is most exposed to Biosimilar risk, Divan says, with Humira accounting for about 60% of its total net present value, and is cautious on AbbVie's outlook in front of biosimilar competition in the EU later this year and in the U.S. by 2023.
06/15/18
JEFF
06/15/18
NO CHANGE
JEFF
Buy
AbbVie removed from Franchise Pick list at Jefferies
Jefferies analyst Ian Hilliker removed AbbVie from his firm's Franchise Pick list but keeps a Buy rating on the shares with a reduced price target of $125. The stock "continues to have an attractive upside based on its valuation," Hilliker tells investors in a research note.
06/11/18
ARGS
06/11/18
NO CHANGE
Target $130
ARGS
Buy
AbbVie price target lowered to $130 from $145 at Argus
Argus analyst David Toung lowered his price target on AbbVie to $130, citing the clinical setback for Rova-T as a treatment for relapsing small cell lung cancer, even though he continues to expect "solid growth" from Humira, Imbruvica, and hepatitis C drugs. Toung also keeps his Buy rating on Abbvie, pointing to the company's "strong product pipeline". The analyst further states that the valuation on AbbVie stock of 11.4-times his expected FY19 EPS is attractive at just below the average industry multiple of 11.9-times given the company's strong growth prospects.

TODAY'S FREE FLY STORIES

TCEHY

Tencent

$0.00

(0.00%)

, MDLA

Medallia

$37.09

(0.00%)

07:31
07/21/19
07/21
07:31
07/21/19
07:31
On The Fly
Opening Day: Start-up DouYou becomes China's biggest Wall Street IPO of 2019 »

Drugmaker Genmab raised…

TCEHY

Tencent

$0.00

(0.00%)

MDLA

Medallia

$37.09

(0.00%)

MIRM

Mirum Pharmaceuticals

$13.51

0.17 (1.27%)

FULC

Fulcrum Therapeutics

$12.49

-0.99 (-7.34%)

PHR

Phreesia

$24.01

-1.15 (-4.57%)

GMAB

Genmab

$18.06

-0.14 (-0.77%)

AMK

AssetMark Financial

$27.71

0.39 (1.43%)

ORCC

Owl Rock

$15.51

0.11 (0.71%)

DOYU

DouYu

$10.50

-0.51 (-4.63%)

NOVA

Sunnova Energy

$0.00

(0.00%)

CSTL

Castle Biosciences

$0.00

(0.00%)

WSG

Wanda Sports

$0.00

(0.00%)

LVGO

Livongo Health

$0.00

(0.00%)

HCAT

Health Catalyst

$0.00

(0.00%)

JNJ

Johnson & Johnson

$130.41

-1.62 (-1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 22

    Jul

  • 23

    Jul

  • 23

    Jul

  • 24

    Jul

  • 24

    Jul

  • 31

    Jul

  • 14

    Aug

  • 09

    Sep

  • 16

    Sep

  • 15

    Oct

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 26

    Jul

PYPL

PayPal

$118.65

-1.22 (-1.02%)

, V

Visa

$179.18

-1.34 (-0.74%)

08:31
07/20/19
07/20
08:31
07/20/19
08:31
Periodicals
MasterCard, Visa among best stocks to play fintech boom, Barron's says »

The fintech units within…

PYPL

PayPal

$118.65

-1.22 (-1.02%)

V

Visa

$179.18

-1.34 (-0.74%)

MA

MasterCard

$275.51

-1.11 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 24

    Jul

  • 30

    Jul

USB

U.S. Bancorp

$54.98

-0.2 (-0.36%)

, SBNY

Signature Bank

$123.87

1.07 (0.87%)

08:28
07/20/19
07/20
08:28
07/20/19
08:28
Periodicals
KeyCorp, U.S. Bancorp better positioned for Fed rate cut, Barron's says »

KeyCorp (KEY), Signature…

USB

U.S. Bancorp

$54.98

-0.2 (-0.36%)

SBNY

Signature Bank

$123.87

1.07 (0.87%)

KEY

KeyCorp

$17.45

0.15 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 29

    Aug

  • 16

    Oct

CMG

Chipotle

$746.80

-17.43 (-2.28%)

08:24
07/20/19
07/20
08:24
07/20/19
08:24
Periodicals
Chipotle stock made 'stunning' comeback, Barron's says »

Chipotle's stock is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 25

    Sep

BYND

Beyond Meat

$176.65

6.28 (3.69%)

07:40
07/20/19
07/20
07:40
07/20/19
07:40
Periodicals
Beyond Meat could spike after earnings, Barron's says »

After rising so…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jul

NFLX

Netflix

$315.10

-10.04 (-3.09%)

07:37
07/20/19
07/20
07:37
07/20/19
07:37
Periodicals
Netflix's problems have only just begun, Barron's says »

Netflix has a problem and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, TGT

Target

$88.02

-0.48 (-0.54%)

07:34
07/20/19
07/20
07:34
07/20/19
07:34
Periodicals
Time to aim higher on Target's stock, Barron's says »

As retailers have…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

TGT

Target

$88.02

-0.48 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 21

    Aug

  • 19

    Sep

  • 25

    Sep

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, FDX

FedEx

$167.08

1.69 (1.02%)

07:31
07/20/19
07/20
07:31
07/20/19
07:31
Periodicals
FedEx ups game amid e-commerce growth, Barron's says »

It is time to embrace…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

FDX

FedEx

$167.08

1.69 (1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 30

    Jul

  • 31

    Jul

  • 17

    Sep

  • 13

    Nov

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, MSFT

Microsoft

$136.62

0.33 (0.24%)

07:27
07/20/19
07/20
07:27
07/20/19
07:27
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

MSFT

Microsoft

$136.62

0.33 (0.24%)

ORCL

Oracle

$57.55

-0.58 (-1.00%)

AZN

AstraZeneca

$40.11

-0.61 (-1.50%)

BMY

Bristol-Myers

$43.32

-0.72 (-1.63%)

LLY

Eli Lilly

$106.75

-1.57 (-1.45%)

GSK

GlaxoSmithKline

$40.97

-0.44 (-1.06%)

JNJ

Johnson & Johnson

$130.41

-1.62 (-1.23%)

MRK

Merck

$81.39

-1.28 (-1.55%)

NVS

Novartis

$93.58

-0.715 (-0.76%)

PFE

Pfizer

$42.78

-0.28 (-0.65%)

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$41.94

-0.01 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 24

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 29

    Jul

  • 30

    Jul

  • 30

    Jul

  • 30

    Jul

  • 03

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 27

    Aug

  • 28

    Aug

  • 02

    Sep

  • 09

    Sep

  • 16

    Sep

  • 16

    Sep

  • 20

    Sep

  • 23

    Sep

  • 25

    Sep

  • 02

    Oct

  • 15

    Oct

  • 04

    Nov

BHVN

Biohaven Pharmaceutical

$44.16

-0.61 (-1.36%)

18:12
07/19/19
07/19
18:12
07/19/19
18:12
Hot Stocks
Biohaven receives CRL from FDA for application seeking NURTEC approval »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

CE

Celanese

$107.01

0.9 (0.85%)

18:01
07/19/19
07/19
18:01
07/19/19
18:01
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

F

Ford

$10.20

-0.06 (-0.58%)

17:48
07/19/19
07/19
17:48
07/19/19
17:48
Periodicals
Ford plans to lay off 185 employees at Ontario plant, Reuters reports »

A union local said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 23

    Oct

RTN

Raytheon

$178.55

2.45 (1.39%)

17:48
07/19/19
07/19
17:48
07/19/19
17:48
Hot Stocks
Raytheon awarded $191.01M Air Force contract modification »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

UTX

United Technologies

$132.37

1.08 (0.82%)

17:44
07/19/19
07/19
17:44
07/19/19
17:44
Hot Stocks
United Technologies awarded $253.71M Air Force contract »

United Technologies has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

LMT

Lockheed Martin

$356.90

0.675 (0.19%)

17:40
07/19/19
07/19
17:40
07/19/19
17:40
Hot Stocks
Lockheed Martin awarded $1.47B Missile Defense Agency contract modification »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

ARES

Ares Management

$28.13

-0.305 (-1.07%)

17:33
07/19/19
07/19
17:33
07/19/19
17:33
Syndicate
Breaking Syndicate news story on Ares Management »

Ares Management files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 06

    Aug

HAFC

Hanmi Financial

$21.68

-0.105 (-0.48%)

17:33
07/19/19
07/19
17:33
07/19/19
17:33
Hot Stocks
Hanmi Financial to delay release of Q2 results »

Hanmi Financial announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

PAYS

Paysign

$17.49

-0.48 (-2.67%)

17:32
07/19/19
07/19
17:32
07/19/19
17:32
Syndicate
Breaking Syndicate news story on Paysign »

Paysign files $150M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEOH

Methanex

$43.19

0.83 (1.96%)

17:28
07/19/19
07/19
17:28
07/19/19
17:28
Hot Stocks
Methanex reaches final investment decision on methanol plant in Geismar, LA »

Methanex Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

17:17
07/19/19
07/19
17:17
07/19/19
17:17
Conference/Events
Credit Suisse biotech analysts to hold an analyst/industry conference call »

Biotech Analysts provide…

17:14
07/19/19
07/19
17:14
07/19/19
17:14
Conference/Events
UBS retail/hardlines analyst to hold an analyst/industry conference call »

Retail/Hardlines Analyst…

SHIP

Seanergy Marine

$0.64

-0.0425 (-6.25%)

17:05
07/19/19
07/19
17:05
07/19/19
17:05
Hot Stocks
Seanergy Maritime receives noncompliance notice from Nasdaq »

Seanergy Maritime…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SONM

Sonim

$13.42

0.24 (1.82%)

16:41
07/19/19
07/19
16:41
07/19/19
16:41
Conference/Events
Sonim management to meet with Oppenheimer »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 26

    Jul

  • 12

    Sep

KINS

Kingstone Companies

$8.81

0.09 (1.03%)

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Hot Stocks
Kingstone names Barry Goldstein CEO »

Kingstone Companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 09

    Aug

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Options
Preliminary option volume of 22.6M today »

Preliminary option volume…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.